Ariel Eva Eber

Ariel Eva Eber

Auto-generated profile, based on publicly available information

Ariel Eva Eber

Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2013 in Anesthesiology
Verified
Journal Article
Open access
PDF file
YZYan Ping Zhang
Yan Ping Zhang
AEAriel Eber
Ariel Eber
YYYue Yuan
Yue Yuan
Zhe YangZhe Yang
Zhe Yang
YRYiliam Rodriguez
Yiliam Rodriguez
KCKeith A. Candiotti
Keith A. Candiotti
Background: Oxidative stress is a key factor implicated in the development of diabetic neuropathy. This study evaluates the prophylactic and antinociceptive effects of the antioxidant coenzyme Q10 (CoQ10) on diabetes-induced neuropathic pain in a diabetic mouse model. Methods: Total 56 mice with type 1 diabetes induced by streptozotocin were used, 20 normal mice were used as control. Mechanical and thermal nociceptive behavioral assays were applied to evaluate diabetic neuropathic pain. Tissue lipid peroxidation, immunohistochemistry, reverse transcription, and polymerase chain reaction were used to evaluate the molecular mechanisms of CoQ10. Data are presented as mean ± SEM. Results: CoQ10 administration was associated with reduced loss of body weight compared with nontreated diabetic mice, without affecting blood glucose levels. Low dose and long-term administration of CoQ10 prevented the development of neuropathic pain. Treatment with CoQ10 produced a significant dose-dependent inhibition of mechanical allodynia and thermal hyperalgesia in diabetic mice. Dorsal root ganglia, sciatic nerve, and spinal cord tissues from diabetic mice demonstrated increased lipid peroxidation that was reduced by CoQ10 treatment. CoQ10 administration was also noted to reduce the proinflammatory factors in the peripheral and central nervous system. Conclusions: The results of this study support the hypothesis that hyperglycemia induced neuronal oxidative damage and reactive inflammation may be pathogenic in diabetic neuropathic pain. CoQ10 may be protective by inhibiting oxidative stress and reducing inflammation by down-regulating proinflammatory factors. These results suggest that CoQ10 administration may represent a low-risk, high-reward strategy for preventing or treating diabetic neuropathy.

1 October 2013 in Neurobiology of Disease
Verified
Journal Article
Closed access
YZYan Ping Zhang
Yan Ping Zhang
CSChun Yu Song
Chun Yu Song
YYYue Yuan
Yue Yuan
AEAriel Eber
Ariel Eber
YRYiliam Rodriguez
Yiliam Rodriguez
KCKeith A. Candiotti
Keith A. Candiotti

8 August 2017 in American Journal of Clinical Dermatology
Verified
Journal Article
Closed access
PDF file
RFRachel A. Fayne
Rachel A. Fayne
MPMarina Perper
Marina Perper
AEAriel E. Eber
Ariel E. Eber
AAAdam S. Aldahan
Adam S. Aldahan
KNKeyvan Nouri
Keyvan Nouri

1 February 2018 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
NVN.E. Vazquez‐Herrera
N.E. Vazquez‐Herrera
AEA.E. Eber
A.E. Eber
MMM.A. Martinez‐Velasco
M.A. Martinez‐Velasco
MPM. Perper
M. Perper
JCJ. Cervantes
J. Cervantes
Antonella TostiAntonella Tosti
Antonella Tosti

14 November 2017 in Drug Safety - Case Reports
Verified
Journal Article
Open access
PDF file
AEAriel E. Eber
Ariel E. Eber
ARAlyx Rosen
Alyx Rosen
KOKate E. Oberlin
Kate E. Oberlin
AGAlessio Giubellino
Alessio Giubellino
PRPaolo Romanelli
Paolo Romanelli
Tyrosine kinase inhibitors have revolutionized the chemotherapy arena as targeted therapies for a multitude of malignancies. They are more selective than conventional chemotherapy, and often elicit fewer systemic adverse events, however toxicities still exist. Cutaneous toxicities are common and their management presents a novel challenge to physicians and patients. Ponatinib is a third-generation tyrosine kinase inhibitor increasingly reported to cause cutaneous eruption. A 50-year-old woman with a history of chronic myelogenous leukemia presented with a 4-month history of worsening atrophic and ichthyosiform pink plaques involving the axillae, thighs and abdomen; red patches were also observed on the cheeks and forehead. She was started on the third-generation, ponatinib, 5 months earlier because of disease refractory to previous therapies including interferon, imatinib, dasatinib and bosutinib. A skin biopsy revealed perifollicular fibrosis, alternating orthokeratosis and parakeratosis, and a sparse perivascular lymphocytic infiltrate consistent with a pityriasis rubra pilaris-like reaction. Topical tretinoin 0.025% cream was initiated, resulting in resolution within 3 weeks without discontinuation of ponatinib. A review of previous reports identified significant similarities among the ponatinib-induced drug reactions. Here, we highlight not only that cutaneous eruptions occur on ponatinib therapy, but that the dermatologic manifestations are characteristic and unique, and benefit from retinoid therapy, without requiring interruption of vital chemotherapy.

28 February 2019 in International Journal of Dermatology
Verified
Journal Article
Closed access
ICIsabella Camacho
Isabella Camacho
ARAli Rajabi-Estarabadi
Ali Rajabi-Estarabadi
AEAriel E. Eber
Ariel E. Eber
JGJacob W. Griggs
Jacob W. Griggs
SMSanchez I. Margaret
Sanchez I. Margaret
ATAntonella Tosti
Antonella Tosti